代表性研究成果（按发表年份排序）：

1.A new perspective on the therapeutic potential of tumor metastasis: targeting the metabolic interactions between TAMs and tumor cells. Int J Biol Sci. 2024 Sep 4. (IF = 8.2)

2.BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy. 2024 May 23.“中国科技期刊卓越行动计划高起点新刊”https://doi.org/10.1016/j.hlife.2024.05.005

3.Expand available targets for CAR-T therapy to overcome tumor drug resistance based on the "Evolutionary Traps". Pharmacol Res. 2024 May 18. doi: 10.1016/j.phrs.2024.107221. Epub 2024 May 18. PMID: 38768669. (IF = 9.1)

4.Bispecific CAR T-cell therapy targeting BCMA and CD19in relapsed/refractory multiple myeloma: a phase l/l trial.Nature communications. 2024 Apr 12.doi: 10.1038/s41467-024-47801-8.（IF =16.6）

5.In vivo manufacture and manipulation of CAR‑T cells for better druggability. Cancer and Metastasis Reviews. 2024 Apr 9. doi: 10.1007/s10555-024-10185-8.（IF = 9.2）

6.CRISPR screens in mechanism and target discovery for AML. Heliyon. 2024 Apr 9. doi: 10.1016/j.heliyon.2024.e29382.（IF =3.4）

7.Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors. BBA-Molecular Basis of Disease. 2024 Apr 5:167159. doi: 10.1016/j.bbadis.2024.167159.（IF = 6.2）

8.Bispecific BCMA/CD19 targeted CAR‑T cell therapy forces sustained disappearance ofsymptoms andanti‑acetylcholine receptor antibodies inrefractory myasthenia gravis: acase report.Journal of Neurology,2024 Apr11,doi.org/10.1007/s00415-024-12367-4（IF = 6.0）

9.AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses. Front Immnunol. 2023 Sep 12:14:1182601. doi: 10.3389/fimmu.2023.1182601.（IF =7.3）

10.Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol. 2022 Jul 10;40(20):2246-2256.（IF = 45.3）

11.Safety and efficacy of a humanized CD19 chimeric antigen receptor T Cells for relapsed/refractory acute lymphoblastic leukaemia. Am J Hematol. 2022 Jun 1;97(6):711-718.（IF = 12.8）

12.Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood. 2022 Jun 9;139(23):3376-3386.（IF = 20.3）

13.An immune-related gene prognostic risk index for pancreatic adenocarcinoma. Front Immnunol.2022,13:945878.（IF = 7.3）

14.Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated. J Immunother Cancer. 2021, 9(1):e001466.（IF = 10.9）

15.CRISPR screen in mechanism and target discovery for cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2020, 1874(1):188378.（IF = 11.2）

16.β2-AR activation promotes cleavage and nuclear translocation of Her2 and metastatic potential of cancer cells. Cancer Sci.2020,111(12):4417-4428.（IF = 5.7）

17.A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019 Oct;6(10):e521-e529.（IF = 24.7）

18.Neural regulation of drug resistance in cancer treatment. Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):20-28.（IF =11.2）